Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Petra Acquisition, Inc. was a publicly traded special purpose acquisition company (SPAC) organized to effect a merger or business combination with an operating company in the healthcare or related sector. It entered into a definitive agreement to merge with Revelation Biosciences, Inc., a clinical-stage biotech company focused on immunologic-based therapies for the prevention and treatment of disease, in late 2021. Upon completion of the merger, Petra Acquisition ceased to exist as an independent entity, and the combined company was renamed Revelation Biosciences, Inc. and listed on NASDAQ under the ticker symbol REVB.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Petra Acquisition.